Yasuhiro Asahina

7.4k total citations · 2 hit papers
129 papers, 4.5k citations indexed

About

Yasuhiro Asahina is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Yasuhiro Asahina has authored 129 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hepatology, 82 papers in Epidemiology and 14 papers in Oncology. Recurrent topics in Yasuhiro Asahina's work include Hepatitis C virus research (78 papers), Liver Disease Diagnosis and Treatment (63 papers) and Hepatitis B Virus Studies (48 papers). Yasuhiro Asahina is often cited by papers focused on Hepatitis C virus research (78 papers), Liver Disease Diagnosis and Treatment (63 papers) and Hepatitis B Virus Studies (48 papers). Yasuhiro Asahina collaborates with scholars based in Japan, United States and Taiwan. Yasuhiro Asahina's co-authors include Namiki Izumi, Masayuki Kurosaki, Fumiaki Marumo, Nobuyuki Enomoto, Ikuo Sakuma, Takeshi Murakami, Chikara Yamamoto, Chifumi Sato, Yuki Ogura and Jun Itakura and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Gastroenterology.

In The Last Decade

Yasuhiro Asahina

115 papers receiving 4.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations in the Nonstructural Protein 5a Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus 1b Infection

1996 829 citations Nobuyuki Enomoto, Ikuo Sakuma et al. profile →
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.

1995 528 citations Naoya Enomoto, Ikuo Sakuma et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yasuhiro Asahina Japan	31	3.8k	3.1k	576	516	419	129	4.5k
Eiji Mita Japan	32	2.4k 0.6×	2.0k 0.7×	480 0.8×	540 1.0×	196 0.5×	120	3.3k
Masataka Tsuge Japan	35	2.5k 0.7×	2.5k 0.8×	209 0.4×	867 1.7×	345 0.8×	189	3.9k
Maria Grazia Rumi Italy	36	4.5k 1.2×	4.2k 1.4×	376 0.7×	256 0.5×	300 0.7×	150	5.3k
Gerd R. Pape Germany	33	4.0k 1.1×	3.3k 1.1×	478 0.8×	329 0.6×	306 0.7×	67	5.2k
Nobuhiko Hiraga Japan	31	2.2k 0.6×	2.1k 0.7×	257 0.4×	465 0.9×	389 0.9×	89	3.0k
Christoph Neumann‐Haefelin Germany	35	2.3k 0.6×	1.8k 0.6×	232 0.4×	593 1.1×	396 0.9×	111	4.0k
David Booth Australia	21	1.8k 0.5×	1.5k 0.5×	473 0.8×	708 1.4×	183 0.4×	35	2.9k
Lynn B. Dustin United States	26	1.7k 0.4×	1.2k 0.4×	396 0.7×	329 0.6×	205 0.5×	43	2.7k
Gary L. Norman United States	38	1.5k 0.4×	1.6k 0.5×	1.4k 2.4×	348 0.7×	194 0.5×	123	4.0k
Kazumoto Murata Japan	30	1.5k 0.4×	1.3k 0.4×	123 0.2×	653 1.3×	346 0.8×	135	2.7k

Countries citing papers authored by Yasuhiro Asahina

Since Specialization

Citations

This map shows the geographic impact of Yasuhiro Asahina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuhiro Asahina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuhiro Asahina more than expected).

Fields of papers citing papers by Yasuhiro Asahina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuhiro Asahina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuhiro Asahina. The network helps show where Yasuhiro Asahina may publish in the future.

Co-authorship network of co-authors of Yasuhiro Asahina

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuhiro Asahina. A scholar is included among the top collaborators of Yasuhiro Asahina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuhiro Asahina. Yasuhiro Asahina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Taniai, Tomohiko, Shu Shimada, Koichiro Haruki, et al.. (2025). Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC. Hepatology. 83(2). 231–248. 2 indexed citations

2.

Gane, Edward, Ewa Janczewska, Tetsuo Takehara, et al.. (2025). Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study. JHEP Reports. 7(10). 101516–101516. 1 indexed citations

3.

Tsuchiya, Jun, Masato Miyoshi, Sei Kakinuma, et al.. (2024). Hepatitis B Virus-KMT2B Integration Drives Hepatic Oncogenic Processes in a Human Gene-edited Induced Pluripotent Stem Cells-derived Model. Cellular and Molecular Gastroenterology and Hepatology. 19(2). 101422–101422. 1 indexed citations

4.

Kaneko, Shun, Yasuhiro Asahina, Miyako Murakawa, et al.. (2024). Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades. PLoS ONE. 19(3). e0297882–e0297882.

5.

Yoshifuji, Kota, Yoshihiro Umezawa, Toshikage Nagao, et al.. (2024). Hepatitis C virus-related hepatitis flare after immunochemotherapy in a patient with follicular lymphoma. Journal of Clinical and Experimental Hematopathology. 64(4). 313–317.

6.

Miyoshi, Masato, Sei Kakinuma, Ayako Sato, et al.. (2024). A20 in hepatic stellate cells suppresses chronic hepatitis by inhibiting DCLK1 – JNK pathway‐dependent chemokines. The FASEB Journal. 38(13). e23757–e23757. 2 indexed citations

7.

Takahama, Shokichi, Sachiyo Yoshio, Ryotaro Sakamori, et al.. (2023). Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8+ T cell quality. Frontiers in Immunology. 14. 1257113–1257113. 7 indexed citations

8.

Takehara, Tetsuo, Kazuaki Chayama, Masayuki Kurosaki, et al.. (2020). JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. Journal of Gastroenterology. 55(6). 640–652. 3 indexed citations

9.

Tamaki, Nobuharu, Masayuki Kurosaki, Mayu Higuchi, et al.. (2015). Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS ONE. 10(9). e0137351–e0137351. 19 indexed citations

10.

Asahina, Yasuhiro, Mina Nakagawa, Sei Kakinuma, & Mamoru Watanabe. (2013). Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response. Journal of Clinical and Translational Hepatology. 1(1). 39–44. 4 indexed citations

11.

Asahina, Yasuhiro, Norio Hayashi, Naoki Hiramatsu, et al.. (2013). Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatology Research. 43(1). 1–34. 22 indexed citations

12.

Nitta, Sayuri, Naoya Sakamoto, Mina Nakagawa, et al.. (2012). Hepatitis C virus NS4B protein targets STING and abrogates RIG-I–mediated type I interferon-dependent innate immunity. Hepatology. 57(1). 46–58. 124 indexed citations

13.

Asahina, Yasuhiro, Namiki Izumi, Makoto Oketani, et al.. (2012). Treatment Guidelines of Hepatitis C. Kanzo. 53(6). 355–395. 2 indexed citations

14.

Tanaka, Yasushi, Nao Nishida, Shuhei Hige, et al.. (2010). 726 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS IN THE HLA-DP LOCUS ASSOCIATED WITH CHRONIC HEPATITIS B. Journal of Hepatology. 52. S282–S283. 3 indexed citations

15.

Kuzuya, Teiji, Kaoru Tsuchiya, Yuichiro Suzuki, et al.. (2010). Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma. Kanzo. 51(7). 403–404. 1 indexed citations

16.

Miyazaki, Akihisa, et al.. (2008). Chronic Viral Hepatitis. Nihon Naika Gakkai Zasshi. 97(1). 108–129.

17.

Asahina, Yasuhiro, Kaoru Tsuchiya, Mitsuaki Sato, et al.. (2008). Two cases of hepatic angiomyolipoma with different ultrasonographic and radiographic findings. Kanzo. 49(9). 440–448. 1 indexed citations

18.

Izumi, Namiki, Yasuhiro Asahina, Osamu Noguchi, et al.. (2001). Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer. 91(5). 949–956. 99 indexed citations

19.

Izumi, Namiki, Yasuhiro Asahina, Osamu Noguchi, et al.. (2001). Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer. 91(5). 949–956. 13 indexed citations

20.

Enomoto, Naoya, Ikuo Sakuma, Yasuhiro Asahina, et al.. (1995). Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.. Journal of Clinical Investigation. 96(1). 224–230. 528 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact